High level expression of functional human IgMs in human PER.C6® cells

mAbs

Volumn 1, Issue 2, 2009, Pages 163-171

  Tchoudakova, Anna ^a   Hensel, Frank ^b   Murillo, Alec ^a   Eng, Bernie ^a   Foley, Marketa ^a   Smith, Lakee ^a   Schoenen, Frank ^b   Hildebrand, Antonia ^b   Kelter, Arndt René ^b   Ilag, Leodevico L ^c,d   Vollmers, H Peter ^e   Brandlein, Stephanie ^e   McIninch, Jane ^a   Chon, John ^a   Lee, Gene ^a   Cacciuttolo, Marco ^a  

^a Percivia LLC   (United States)

^b Patrys GmbH   (Germany)

^c Patrys Ltd   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Expression; Hexamer; IgM; J chain; Pentamer; PER.C6

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M;

ARTICLE; BINDING ASSAY; CELL LINE; CELL LINE PER.C6; CYTOTOXICITY; FED BATCH CULTURE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SUSPENSION CELL CULTURE;

EID: 77953676981     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.2.7945     Document Type: Article

References (26)

1. Kohler G and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497
2. Reichert JM and Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nature Reviews 2007; 6:349-356 (Pubitemid 46696550)
3. Collins C, Tsui FWL, Shulman MJ. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur J Immunol 2002; 32:1802-1810 (Pubitemid 34679168)
4. Wiersma EJ, Collins C, Fazel S, Shulman MJ. Structural and functional analysis of J chain-deficient IgM. J Immunol 1998; 160:5979-5989 (Pubitemid 28298059)
5. Irie RF, Ollila DW, O'Day S, Morton DL. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother 2004; 53:110-117 (Pubitemid 38161217)
6. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981; 66:249-254 (Pubitemid 11117626)
7. Ollert MW, David K, Schmitt C, Hauenschild A, Bredehorst R, Erttmann R, et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci USA 1996; 93:4498-4503 (Pubitemid 26144315)
8. Vollmers HP, O'Connor R, Muller J, Kirchner T, Muller-Hermelink HK. SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 1989; 49:2471-2476 (Pubitemid 19125581)
9. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003; 63:7995-8005. (Pubitemid 37466738)
10. Vollmers HP and Brandlein S. Natural antibodies and cancer. J Autoimmune. 2007; 29:295-302.
11. Wurm F. Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnology 2004; 22:1393-1398 (Pubitemid 39482858)
12. Cattaneo A and Neuberger MS. Polymeric immunoglobulin M is secreted by transfectants of non lymphoid cells in the absence of immunoglobulin J chain. EMBO J 1987; 6:2753-2758
13. Cacciuttolo MA, Patchan M, Lamey K, Allikmets E, Tsao E. Large-scale production of a monoclonal IgM in a hybridoma suspension culture. BioPharm 1998; 20-29 (Pubitemid 28216062)
14. Wood CR, Dorner AJ, Morris GE, Alderman EM, Wilson D, O'Hara RM Jr, Kaufman RJ. High level synthesis of immunoglobulins in Chinese hamster ovary cells. J Immunol 1990; 145:3011-3016 (Pubitemid 20382574)
15. Barnes LM, Bentley CM, Dickson AJ. Stability of protein production from recombinant mammalian cells. Biotechnol Bioeng 2003; 81:631-639 (Pubitemid 36258516)
16. Faller G, Vollmers HP, Weiglein I, Marx A, Zink C, Pfaff M, Muller-Hermelink HK. HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies. Br J Cancer 1990; 62:595-598 (Pubitemid 20340571)
17. Brandlein S and Vollmers HP. Natural IgM antibodies, the ignored weapons in tumor immunity. Histol Histopathol 2004; 897-905. (Pubitemid 38855071)
18. Vollmers HP and Brandlein S. Death by stress: natural IgM-induced apoptosis. Methods Find Exp Clin Pharmacol 2005; 27:185-191 (Pubitemid 40571213)
19. Brandlein S, Lorenz J, Ruoff N, Hensel F, Beyer I, Muller J, et al. Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum Antibodies 2002; 11:107-119 (Pubitemid 36470163)
20. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, et al. Highlevel expression of recombinant IgG in the human cell line PER.C6®. Biotechnol Prog 2003; 19:163-168 (Pubitemid 36219317)
21. DSM and Crucell press release, "DSM and Crucell announce another key achievement for PER.C6® technology: scaleup of high titer fed-batch process to 250 liters." 2008.
22. Brandlein S, Rauschert N, Rasche L, Dreykluft A, Hensel F, Conzelmann E, et al. The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized lowdensity lipoprotein. Mol Cancer Ther 2007; 6:326-333 (Pubitemid 46206697)
23. Randall TD, Brewer JW, Corley RB. Direct evidence that J chain regulates the polymeric structure of IgM in antibody-secreting B cells. J Bio Chem 1992; 267:18002-18007
24. Tagliavacca L, Anelli T, Fagioli C, Mezghrani A, Ruffato E, Sitia R. The making of a professional secretory cell: architectural and functional changes in the ER during B lymphocyte plasma cell differentiation. Biol Chem 2003; 384:1273-1277 (Pubitemid 37168694)
25. Kimura N, Toyonaga B, Yoshikai Y, Du R, Mak TW. Sequences and repertoire of the human T cell receptor α and β chain variable region genes in thymocytes. Eur J Immunol 1987; 17:375-383 (Pubitemid 17060792)
26. Gagnon P, Hensel F, Richieri R. Purification of IgM Monoclonal Antibodies: Manufacturing challenges surround the use of IgM monoclonal. BioPharm Int Sup 2008; 26-36.